Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Israel journal of medical sciences

• Publication date

  1994-08-01

• Fields of study

  Medicine

• Identifiers
  PMID 8045754
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of iron-chelating agents for clinical use.

  1992cited by this paper
• Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine

  1992cited by this paper
• Growth failure and bony changes induced by deferoxamine.

  1992cited by this paper
• Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.

  1991cited by this paper
• Right Atrial Catheters in Children with Cancer: A Decade of Experience in the Use of Tunnelled, Exteriorized Devices at a Single Institution

  1991cited by this paper
• Complications of Indwelling Venous Access Lines in the Pediatric Hematology Patient: A Prospective Comparison of External Venous Catheters and Subcutaneous Ports

  1991cited by this paper
• Management of thalassemia major (Cooley's anemia).

  1991cited by this paper
• Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major.

  1990cited by this paper
• Survival and causes of death in thalassaemia major.

  1989cited by this paper
• Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy.

  1989cited by this paper
• Neurotoxicity associated with deferoxamine therapy.

  1988cited by this paper
• A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study.

  1988cited by this paper
• Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion.

  1987cited by this paper
• Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.

  1986cited by this paper
• Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

  1985cited by this paper
• Growth and sexual maturation in thalassemia major.

  1985cited by this paper
• Visual loss in patient on high-dose subcutaneous desferrioxamine.

  1984cited by this paper
• Ocular toxicity of high-dose intravenous desferrioxamine.

  1983cited by this paper
• Iron chelation therapy with deferoxamine in Cooley anemia.

  1978cited by this paper
• Variations in the Pattern of Pubertal Changes in Boys

  1970cited by this paper
• Variations in pattern of pubertal changes in girls.

  1969cited by this paper
• Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II.

  1966cited by this paper
• Current therapeutics. 213. Desferrioxamine.

  1965cited by this paper

• Treating thalassemia major-related iron overload: the role of deferiprone

  2012cites this paper
• Iron chelation in thalassemia: time to reconsider our comfort zones

  2011cites this paper
• Journal of Cardiovascular Magnetic Resonance Open Access Combined Chelation Therapy in Thalassemia Major for the Treatment of Severe Myocardial Siderosis with Left Ventricular Dysfunction

  2008cites this paper
• Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.

  2006cites this paper
• Weekend Very High-dose Intravenous Deferoxamine in Children With Transfusional Iron Overload

  2006cites this paper
• Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance.

  2005cites this paper
• Reversal of cardiac complications in thalassemia major by long‐term intermittent daily intensive iron chelation

  2003cites this paper
• Cardiac complications in thalassemia: noninvasive detection methods and new directions in the clinical management

  2003cites this paper
• Right atrial thrombus formation associated with central venous catheters utilization in hemodialysis patients

  2003influential citation
• Results of long term iron chelation treatment with deferoxamine.

  2002cites this paper
• Cardioprotective effect of iron chelators.

  2002cites this paper
• Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia

  2000cites this paper
• Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.

  2000cites this paper
• Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk b-thalassemia

  2000cites this paper
• Continuous low-dose subcutaneous desferrioxamine (DFO) to prevent allergic manifestations in patients with iron overload

  1996cites this paper
• High‐dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration

  1996cites this paper